The global biopsy devices market is projected to reach USD 12.6 billion by 2028 from USD 6.6 billion in 2023, at a CAGR of 14.0% from 2023 to 2028. Factors such as the the rising incidence of cancer and other chronic diseases has spurred the need for more frequent and accurate tissue sampling. Moreover, increased awareness of the importance of early disease detection and personalized medicine has driven demand for advanced biopsy devices.

“The Needle based biopsy instruments segment of product segment l held the largest share of the market in 2022”
Based on product, the biopsy devices market is segmented into needle based biopsy instruments, localization wire, biopsy forceps, procedure tray, biopsy table and other products. The needle based biopsy instruments segment held a major share of the market. advancements in needle biopsy technologies, such as improved guidance systems and the development of more specialized needles for different tissue types, have increased the accuracy and reliability of these procedures, further driving their adoption.

“The breast biopsy segment is projected to register the highest CAGR during the forecast period”
Based on application, the biopsy devices market is segmented into breast, lung, kidney, colorectal, bone marrow, prostate and other applications. The breast biopsy segment accounted for the largest market share in 2022. breast cancer remains one of the most prevalent cancers globally, emphasizing the critical role of early and accurate diagnosis. As breast cancer awareness and screening programs expand, the demand for biopsy procedures to confirm diagnoses and determine treatment strategies is on the rise.

“The diagnostic imaging centers segment for end user segment is projected to register a significant CAGR during the forecast period”
On the basis of end user, the biopsy devices market is segmented into hospitals and breast care centers, diagnostic imaging cneters, academic and research institutes. The diagnostic imaging centers segment accounted for the significant share of the biopsy devices market in 2022. By advanced biopsy deives diagnostic imaging centers can provide more accurate and reliable diagnoses, leading to better treatment planning and improved patient outcomes. Moreover, the versatility of biopsy devices imaging enables these centers to cater to a wide range of medical specialties, effectively serving patients with diverse healthcare needs.

“The market in the North America region is expected to witness the highest growth during the forecast period.”
The biopsy devices market in the North America region is expected to register a CAGR during the forecast period, primarily due to the high healthcare spending in the region, rising prevalence of target diseases, increasing research activities, growing number of cosmetic surgeries, and technological advancements in imaging systems.

A breakdown of the primary participants referred to for this report is provided below:

  • By Company Type: Tier 1–48%, Tier 2–36%, and Tier 3– 16%
  • By Designation: Director-level–14%, C-level–10%, and Others–76%
  • By Region: North America–40%, Europe–32%, Asia Pacific–20%, Latin America–5%, and the Middle East & Africa–3%

The prominent players in the biopsy devices market are Becton, Dickinson and Company (US), Cook Group Incorporated (US), Devicor Medical Products, Inc., (Leica Biosystems) (US), Hologic, Inc. (US), Argon Medical Devices (US), B. Braun SE (Germany), Cardinal Health, Inc. (US), Olympus Corporation (Japan), Boston Scientific Corporation (US), FUJIFILM Holdings Corporation (Japan), INRAD, Inc. (US), and Medtronic plc (Ireland) among others.

Research Coverage
This report studies the biopsy devices market based on technology, display, portability, component, application, enduser, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).

Reasons To Buy the Report
The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall biopsy devices market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.

This report provides insights on the following pointers:

  • Analysis of key drivers (rising target patient population, growing adoption of biopsy devices imaging devices, technological advancement, and increasing investment, funds, and grants by public-private organizations), restraints (high capital and operational cost, unfavorable regulatory guidelines), opportunities (improving healthcare infrastructure across emerging countries, biopsy devices utilization for breast imaging, promising product pipeline), and challenges (availability of alternate imaging technologies) influencing the growth of the biopsy devices market
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the biopsy devices market
  • Market Development: Comprehensive information about lucrative markets–the report analyses the biopsy devices market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the biopsy devices market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Becton, Dickinson and Company (US), Cook Group Incorporated (US), Devicor Medical Products, Inc., (Leica Biosystems) (US), Hologic, Inc. (US), Argon Medical Devices (US), B. Braun SE (Germany), Cardinal Health, Inc. (US), Olympus Corporation (Japan), and Boston Scientific Corporation (US) among others.